WallStreetZenWallStreetZen

NASDAQ: CRON
Cronos Group Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their CRON stock forecasts and price targets.

Forecast return on equity

Is CRON forecast to generate an efficient return?

Company
N/A
Industry
35.44%
Market
202.3%

Forecast return on assets

Is CRON forecast to generate an efficient return on assets?

Company
N/A
Industry
19.13%

CRON earnings per share forecast

What is CRON's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.07
Avg 2 year Forecast
$0.11

CRON revenue forecast

What is CRON's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$180.9M+36.68%
Avg 2 year Forecast
$154.7M+16.91%
Avg 3 year Forecast
$166.0M+25.4%
CRON's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRON revenue growth forecast

How is CRON forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
6.41%
Industry
35.74%
Market
23.59%
CRON's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRON's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRON vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
CRON$2.66N/AN/A
TLRY$7.85$105.00+1,237.58%Buy
PCRX$20.38$30.75+50.88%Buy
AMPH$26.12$30.25+15.81%Hold
ESPR$3.46$12.50+261.27%Strong Buy
View Top Pharmaceutical Stocks

Cronos Group Stock Forecast FAQ

What is CRON's earnings growth forecast for 2026-2027?

(NASDAQ: CRON) Cronos Group's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 51.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.49%.

Cronos Group's earnings in 2026 is $36,098,000.On average, 4 Wall Street analysts forecast CRON's earnings for 2026 to be $27,338,579, with the lowest CRON earnings forecast at $22,514,124, and the highest CRON earnings forecast at $32,163,034.

In 2027, CRON is forecast to generate $42,960,625 in earnings, with the lowest earnings forecast at $41,275,894 and the highest earnings forecast at $44,224,172.

If you're new to stock investing, here's how to buy Cronos Group stock.

What is CRON's revenue growth forecast for 2026-2028?

(NASDAQ: CRON) Cronos Group's forecast annual revenue growth rate of 6.41% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 35.74%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.59%.

Cronos Group's revenue in 2026 is $132,357,000.On average, 4 Wall Street analysts forecast CRON's revenue for 2026 to be $69,265,392,000, with the lowest CRON revenue forecast at $52,421,917,185, and the highest CRON revenue forecast at $86,438,155,025. On average, 3 Wall Street analysts forecast CRON's revenue for 2027 to be $59,248,904,136, with the lowest CRON revenue forecast at $56,924,742,005, and the highest CRON revenue forecast at $60,991,068,500.

In 2028, CRON is forecast to generate $63,548,795,524 in revenue, with the lowest revenue forecast at $61,056,160,356 and the highest revenue forecast at $65,417,314,667.

What is CRON's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CRON) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 19.13%.

What is CRON's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: CRON) Cronos Group's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that CRON's EPS will be $0.07 for 2026, with the lowest EPS forecast at $0.06, and the highest EPS forecast at $0.08. In 2027, CRON's EPS is forecast to hit $0.11 (min: $0.11, max: $0.12).

What is CRON's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CRON) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.